Advertisement
Singapore markets open in 6 hours 2 minutes

  • Straits Times Index

    3,367.90
    +29.33 (+0.88%)
     

  • S&P 500

    5,498.87
    +23.78 (+0.43%)
     

  • Dow

    39,272.31
    +102.79 (+0.26%)
     

  • Nasdaq

    18,009.59
    +130.29 (+0.73%)
     

  • Bitcoin USD

    62,273.16
    -1,345.73 (-2.12%)
     

  • CMC Crypto 200

    1,315.49
    -29.02 (-2.16%)
     

  • FTSE 100

    8,121.20
    -45.56 (-0.56%)
     

  • Gold

    2,336.10
    -2.80 (-0.12%)
     

  • Crude Oil

    82.93
    -0.45 (-0.54%)
     

  • 10-Yr Bond

    4.4440
    -0.0350 (-0.78%)
     

  • Nikkei

    40,074.69
    +443.63 (+1.12%)
     

  • Hang Seng

    17,769.14
    +50.53 (+0.29%)
     

  • FTSE Bursa Malaysia

    1,597.96
    -0.24 (-0.02%)
     

  • Jakarta Composite Index

    7,125.14
    -14.48 (-0.20%)
     

  • PSE Index

    6,358.96
    -39.81 (-0.62%)
     

Compared to Estimates, AbbVie (ABBV) Q2 Earnings: A Look at Key Metrics

Zacks Equity Research
·3-min read

AbbVie (ABBV) reported $13.87 billion in revenue for the quarter ended June 2023, representing a year-over-year decline of 4.9%. EPS of $2.91 for the same period compares to $3.37 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $13.52 billion, representing a surprise of +2.54%. The company delivered an EPS surprise of +4.30%, with the consensus EPS estimate being $2.79.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how AbbVie performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Net Revenue- Venclexta- US: $265 million versus $285.11 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +4.7% change.

  • Net Revenue- Venclexta- International: $306 million versus $270.75 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +21.4% change.

  • Net Revenue- Imbruvica- International: $241 million versus $231.17 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -14.8% change.

  • Net Revenue- Imbruvica- US: $666 million versus the five-analyst average estimate of $643.41 million. The reported number represents a year-over-year change of -22.7%.

  • Net Revenue- Mavyret: $387 million versus $364.05 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -2.8% change.

  • Net Revenue- Lumigan/Ganfort: $119 million versus the five-analyst average estimate of $126.20 million. The reported number represents a year-over-year change of -8.5%.

  • Net Revenue- Ubrelvy- Total: $196 million versus $202.37 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +6% change.

  • Net Revenue- Hematologic Oncology- Total: $1.48 billion versus $1.43 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -10.4% change.

  • Net Revenue- Immunology- Total: $6.81 billion versus $6.60 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -5.5% change.

  • Net Revenue- Other Neuroscience- Total: $70 million compared to the $57.48 million average estimate based on five analysts. The reported number represents a change of -53.3% year over year.

  • Net Revenue- Other Aesthetics- Total: $331 million versus $316.15 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -0.3% change.

  • Net Revenue- Aesthetics- Total: $1.38 billion versus $1.33 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +1% change.

View all Key Company Metrics for AbbVie here>>>

Shares of AbbVie have returned +7.1% over the past month versus the Zacks S&P 500 composite's +5.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research